MINUTES
About Minutes
Back to latest

SocietyCEO turned informant: How the FDA built a case against executives promising cheap medications

A court record says the FDA’s unprecedented criminal case against an alternative funding program hinged on cooperation from a fellow CEO.

FDAcriminal caselow-cost medications

CCNBC★★☆☆☆2026-11-18 21:07Original

CEO turned informant: How the FDA built a case against executives promising cheap medications
CEO turned informant: How the FDA built a case against executives promising cheap medicationsSociety